Bio Pharma SHAKTI scheme

1. At a Glance

Biopharma SHAKTI = Strategy for Healthcare Advancement through Knowledge, Technology & Innovation; a Government of India scheme to build a globally competitive ecosystem for biologics and biosimilars [S1][S2].
Outlay of ₹10,000 crore over 5 years, under the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers [S1].
Targets India's shifting disease burden toward non-communicable diseases (diabetes, cancer, autoimmune disorders) where biologics are critical [S1].
Strategic significance: positions India as a global biopharma manufacturing & innovation hub, complementing PLI-Pharma and the Bio-E3 policy [S1][S3].

Announced in Union Budget 2026-27 (Feb 2026) by Finance Minister to catalyse India's role in the "next industrial revolution" of biomanufacturing [S3][S4].
Operational details of the scheme released by PIB on 10 March 2026 by Department of Pharmaceuticals [S1].

Anchored in the Budget 2026-27 push to make India a global biopharma hub, building on prior pharma sector interventions (PLI for Bulk Drugs/APIs, PLI for Pharmaceuticals, Bio-E3 Policy 2024) [S3][S4].
Driven by India's transition from communicable to non-communicable disease (NCD) burden, raising demand for affordable biologics [S1].
Complements the existing NIPER network (created under NIPER Act, 1998) and CDSCO regulatory apparatus [S2].

Full form: Strategy for Healthcare Advancement through Knowledge, Technology & Innovation [S2].
Nodal Ministry: Ministry of Chemicals & Fertilizers — Department of Pharmaceuticals [S1].
Outlay: ₹10,000 crore [S1]; Duration: 5 years [S1].
Four pillars / components [S2]: 1. Biopharma Discovery Grant Fund + Discovery & Development Equity Fund. 2. Biopharma-focused NIPER Network + National Biopharma R&D Network — 3 new NIPERs + upgradation of 7 existing NIPERs. 3. India Clinical Trial Sites Network — 1,000 accredited sites under ICMR. 4. Fermentation-based Bulk Drugs & Building Blocks Manufacturing Incentive.
Regulatory reform: dedicated Scientific Review Cadre within CDSCO; specialist positions for gene therapy and advanced biologics [S2].
Sectoral focus: biologics, biosimilars, gene therapies, vaccines, bulk biologic intermediates [S2].

Economic
Addresses import dependence in biologics; aims to capture global biosimilar market share [S1][S2].
Creates ancillary demand (filtration, fermentation equipment, precision packaging) — SME opportunity [S2].
Scientific / Technological
Funds discovery-stage R&D via grant + equity instruments — moves India up the value chain from generic-API to innovator biologics [S2].
Strengthens clinical trial infrastructure (1,000 ICMR-accredited sites) to enable globally credible trials [S2].
Social / Health
Targets affordability of biologics for NCDs (cancer, diabetes, autoimmune) — directly linked to SDG-3 [S1].
Administrative / Governance
CDSCO upgrade addresses long-standing complaint of slow biologic approvals; specialist cadre for gene/cell therapy [S2].
Multi-agency design: DoP (scheme), ICMR (trials), CDSCO (regulation), NIPERs (R&D) — coordination is the bottleneck risk.
Geopolitical / Strategic
Aligned with goal of Atmanirbhar Bharat in pharma; reduces dependence on Chinese fermentation-based KSMs/APIs [S2].

Feb 2026: Biopharma SHAKTI announced in Union Budget 2026-27 [S3][S4].
Feb 2026: PIB release on "Budget push to make India a global biopharma hub" [S4].
10 March 2026: Department of Pharmaceuticals issues detailed press release on the scheme [S1].
2026: ₹13,000 crore combined provision flagged in PIB for Biopharma SHAKTI + 3 dedicated chemical parks as a "strategic bet" [S5].

SHAKTI = Strategy for Healthcare Advancement through Knowledge, Technology & Innovation [S2].
Nodal ministry: Chemicals & Fertilizers, Department of Pharmaceuticals (NOT Ministry of Health) [S1].
Outlay: ₹10,000 crore / 5 years [S1].
Announced in Union Budget 2026-27 [S3].
Targets biologics and biosimilars specifically [S1].
3 new NIPERs to be established; 7 existing NIPERs to be upgraded [S2].
Clinical trial network: 1,000 sites, accredited under ICMR [S2].
Includes Fermentation-based Bulk Drugs & Building Blocks manufacturing incentive [S2].
CDSCO to get a dedicated Scientific Review Cadre for advanced biologics including gene therapy [S2].
Has both a Grant Fund and an Equity Fund component for discovery [S2].

GS-III: Indian Economy — Growth & Development; Science & Technology — indigenisation of technology, developments in biotech.
GS-II: Government policies and interventions for development in the health sector.
Plausible question stems: 1. "Biopharma SHAKTI marks India's transition from a generic-pharmacy of the world to a biologics innovator." Critically examine. 2. Discuss how the Biopharma SHAKTI scheme addresses the twin challenges of India's NCD disease burden and import dependence in biologics. 3. Evaluate the role of regulatory reform (CDSCO) and clinical trial infrastructure in realising the goals of Biopharma SHAKTI.

Bio-E3 Policy 2024 — overarching framework for bio-manufacturing and bio-economy.
PLI Scheme for Pharmaceuticals & Bulk Drugs/APIs — input-side import substitution.
NIPER Act, 1998 — institutional backbone touched by SHAKTI.
CDSCO & New Drugs and Clinical Trials Rules, 2019 — regulatory ecosystem.
ICMR — accreditor of the 1,000-site trial network.
Jan Aushadhi (PMBJP) — affordability complement on the demand side.
National Biopharma Mission (BIRAC/DBT) — predecessor in biopharma R&D push.
WHO TRIPS & biosimilar IP regime — global trade dimension.

Wrong ministry: scheme sits under Department of Pharmaceuticals (Chem & Fert), NOT Ministry of Health & Family Welfare or DBT [S1].
Confusing SHAKTI with the SHAKTI coal-linkage policy (Power Ministry) — unrelated.
Mixing up outlays — Biopharma SHAKTI alone is ₹10,000 cr; the ₹13,000 cr figure includes 3 chemical parks too [S1][S5].
Trial sites are accredited under ICMR, not CDSCO [S2].
Scheme is for biologics/biosimilars, NOT a generic-pharma PLI extension.

[S1] Bio Pharma SHAKTI scheme — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2237416 — (tier: 1)
[S2] Biopharma SHAKTI Scheme — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2241168&reg=3&lang=1 — (tier: 1)
[S3] Budget 2026–27 announcement of Biopharma Shakti — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221778&reg=3&lang=2 — (tier: 1)
[S4] Budget Push to Make India a Global Biopharma Hub — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221492&reg=3&lang=1 — (tier: 1)
[S5] ₹13,000 cr for BioPharma SHAKTI & 3 Dedicated Chemical Parks — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2235160&reg=3&lang=1 — (tier: 1)